GPBAR1

G-protein coupled bile acid receptor 1 · Q8TDU6 · GPBAR1 on Sugi Atlas →

124,689 patent compounds predicted against GPBAR1, 77,926 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Chenodiol (SCHEMBL25055)	1.00	14/20
Chenodiol (SCHEMBL25056)	1.00	14/20
Ursodiol (SCHEMBL27200)	1.00	14/20
Chenodiol (SCHEMBL27201)	1.00	14/20
Chenodiol (SCHEMBL209535)	1.00	14/20
Chenodiol (SCHEMBL288251)	1.00	14/20
Chenodiol (SCHEMBL61536)	0.98	14/20
SCHEMBL231848	0.75	13/20
Taurochenodeoxycholate (SCHEMBL40763)	1.00	12/20
Taurursodiol (SCHEMBL40764)	1.00	12/20
Taurochenodeoxycholate (SCHEMBL56779)	1.00	12/20
Taurochenodeoxycholate (SCHEMBL56780)	1.00	12/20
Taurochenodeoxycholate (SCHEMBL287762)	1.00	12/20
Taurochenodeoxycholate (SCHEMBL288610)	0.97	12/20
SCHEMBL132512	0.68	12/20
SCHEMBL55596	0.64	12/20
SCHEMBL160601	0.41	12/20
Glycoursodeoxycholic Acid (SCHEMBL59881)	1.00	11/20
Glycoursodeoxycholic Acid (SCHEMBL231609)	1.00	11/20
Glycochenodeoxycholate (SCHEMBL236354)	1.00	11/20

Clinical trials — most relevant to GPBAR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases	PHASE4	UNKNOWN
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
Effect of the Sequestrant Colesevelam in Bile Acid Diarrhoea	PHASE4	COMPLETED
Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes	PHASE3	NOT_YET_RECRUITING
BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases	PHASE2/PHASE3	WITHDRAWN
Fibrates in Pediatric Cholestasis	PHASE2	COMPLETED
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis	PHASE2	ACTIVE_NOT_RECRUITING
Cholic Acid for Hepatic Steatosis in Lipodystrophy	PHASE2	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Effect of Bile Acids on the Secretion of Satiation Peptides in Humans	PHASE1	COMPLETED
Drug Interaction and Food Effect Study of CS0159	PHASE1	COMPLETED
Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CT	EARLY_PHASE1	COMPLETED
Gut Microbiota and Modulation of Liver Damage in NAFLD	nan	COMPLETED
Bile Acid-induced GLP-secretion. A Study in Cholecystectomized Subjects	nan	COMPLETED
Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT	nan	COMPLETED
FGF19 in Obstructive Cholestasis: Unveil the Signal	nan	UNKNOWN
The Effect of Sleeve Gastrectomy on Post-prandial Serum Bile Acids	nan	COMPLETED
The Metabolic Profile in Intrahepatic Cholestasis of Pregnancy and Diabetes Mellitus	nan	COMPLETED
Effects of Colesevelam HCl On Bile Acid Kinetics	nan	COMPLETED
Evaluation of Trimethylamine N-oxide (TMAO) Levels in Periodontal Disease	nan	COMPLETED
Importance of Meal Fat Content and Gall Bladder Emptying for Postprandial GLP-1 Secretion in Type 2 Diabetes Patients	nan	COMPLETED
Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response	nan	ENROLLING_BY_INVITATION
The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease.	nan	RECRUITING
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation	nan	COMPLETED
Regulation of Human Intestinal Bile Acid Transport in Health and Disease	nan	COMPLETED
The Gut Microbiota and Metabolites in HFpEF	nan	ENROLLING_BY_INVITATION
Mechanisms of Glucose Lowering Effect of Colesevelam HCl	nan	COMPLETED
Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans.	nan	COMPLETED
Pediatric Evaluation and Registry for Liver Cholestasis in Canada	nan	RECRUITING
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a GPBAR1 binder may also engage these)

Protein	Name	Similarity
Q80T02	—	1.000	Q80T02 →
Q862A8	—	1.000	Q862A8 →
Q80SS6	—	0.995	Q80SS6 →
Q862A9	—	0.994	Q862A9 →
Q80UC6	—	0.980	Q80UC6 →
HTR6	5-hydroxytryptamine receptor 6	0.976	landscape →
Q9BZJ7	—	0.975	Q9BZJ7 →
Q8BL07	—	0.972	Q8BL07 →
Q95252	—	0.972	Q95252 →
P31388	—	0.972	P31388 →
ADRB3	Beta-3 adrenergic receptor	0.972	landscape →
RXFP4	Relaxin-3 receptor 2	0.971	landscape →
Q96P69	—	0.971	Q96P69 →
Q28524	—	0.970	Q28524 →
Q9R1C8	—	0.970	Q9R1C8 →
Q7TQP4	—	0.967	Q7TQP4 →
Q5IS65	—	0.967	Q5IS65 →
Q9XT57	—	0.966	Q9XT57 →
Q76JU9	—	0.966	Q76JU9 →
Q9XT58	—	0.966	Q9XT58 →
GALR2	Galanin receptor type 2	0.966	landscape →
Q8NGU9	—	0.965	Q8NGU9 →
Q8K3T4	—	0.965	Q8K3T4 →
Q95LF3	—	0.964	Q95LF3 →
P46626	—	0.963	P46626 →
Q864F5	—	0.963	Q864F5 →
Q9TU05	—	0.962	Q9TU05 →
Q864H9	—	0.961	Q864H9 →
O00155	—	0.961	O00155 →
Q7TQP2	—	0.961	Q7TQP2 →